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Current drug development in oncology is non-selective as it typically focuses on pathways
essential for the survival of all dividing cells. The unique metabolic proﬁle of cancer,
which is characterized by increased glycolysis and suppressed mitochondrial glucose
oxidation (GO) provides cancer cells with a proliferative advantage, conducive with
apoptosis resistance and even increased angiogenesis. Recent evidence suggests that
targeting the cancer-speciﬁc metabolic and mitochondrial remodeling may offer selectivity
in cancer treatment. Pyruvate dehydrogenase kinase (PDK) is a mitochondrial enzyme
that is activated in a variety of cancers and results in the selective inhibition of pyruvate
dehydrogenase, a complex of enzymes that converts cytosolic pyruvate to mitochondrial
acetyl-CoA, the substrate for the Krebs’ cycle. Inhibition of PDK with either small
interfering RNAs or the orphan drug dichloroacetate (DCA) shifts the metabolism of cancer
cells from glycolysis to GO and reverses the suppression of mitochondria-dependent
apoptosis. In addition, this therapeutic strategy increases the production of diffusible Krebs’
cycle intermediates and mitochondria-derived reactive oxygen species, activating p53 or
inhibiting pro-proliferative and pro-angiogenic transcription factors like nuclear factor of
activated T cells and hypoxia-inducible factor 1α. These effects result in decreased tumor
growth and angiogenesis in a variety of cancers with high selectivity. In a small but
mechanistic clinical trial in patients with glioblastoma, a highly aggressive and vascular
form of brain cancer, DCA decreased tumor angiogenesis and tumor growth, suggesting
that metabolic-targeting therapies can be translated directly to patients. More recently,
the M2 isoform of pyruvate kinase (PKM2), which is highly expressed in cancer, is
associated with suppressed mitochondrial function. Similar to DCA, activation of PKM2
in many cancers results in increased mitochondrial function and decreased tumor growth.
Therefore, reversing the mitochondrial suppression with metabolic-modulating drugs, like
PDK inhibitors or PKM2 activators holds promise in the rapidly expanding ﬁeld of metabolic
oncology.
Keywords: mitochondria, tumor metabolism, dichloroacetate, pyruvate dehydrogenase kinase, hypoxia-inducible
factor 1α, apoptosis resistance
INTRODUCTION
Traditional drug development in oncology has focused on path-
ways that are essential for the survival of all cells. The major
limitation of this approach is the selectivity of treatment to can-
cer cells. Alternatively, selectivity to cancer cells can be achieved
by targeting non-essential pathways that are only critical for the
survival of cancer cells, but this approach has limited efﬁcacy.
Overall, it is difﬁcult to target both selective and essential pathways
in current oncology, although there are exceptions. For exam-
ple, chronic myelogenous leukemia (CML) cells dependence on
BCR-ABL tyrosine kinase is induced by a chromosomal translo-
cation only in the malignant cells (Rowley, 1973), making Gleevec
a selective and effective treatment for CML (Kamb et al., 2007).
Similarly, herceptin, an antibody that inhibits human epidermal
growth factor receptor 2 (HER2) on HER2-positive breast cancers
(Eisenhauer, 2001; Slamon et al., 2001) is also selective and effec-
tive, but like Gleevec this is an exception in oncology. In addition,
most cancers are heterogeneous in nature and can adapt when
non essential factors are targeted with non-essential therapy. For
example, in glioblastomamultiform (GBM), even within the same
tumor, one cell may have a different molecular abnormality than
its neighbor cells, making the development of effective therapies
very difﬁcult, keeping the survival of these patients impressively
low (Wen and Kesari, 2008).
In order to address this heterogeneity in oncology, integrative
pathways that are also essential for the survival of cancer, but
not normal cells, need to be targeted. Targeting such a pathway
“distally” may address the fact that several “proximal” signals (for
example several different oncogenes) maybe activated in any given
cancer. The unique metabolism of most solid tumors integrates
many molecular and genetic proximal signals, which all result in
a switch in metabolism from mitochondria-based glucose oxida-
tion (GO) to cytoplasm-based glycolysis even under normoxia,
also known as the Warburg effect (Warburg, 1956; Michelakis
et al., 2008; Vander Heiden et al., 2009; Dromparis et al., 2010).
Thismetabolic proﬁlemay offer selectivity since it clearly separates
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cancer fromnon-cancerous tissues. This is evident by the very high
uptake of glucose measured by positron-emission tomography
(PET) in cancer, compared to the neighboring non-cancer tissues,
making PET one of the most sensitive tools to diagnose cancer.
At the same time, it is now clear that this metabolic switch offers
a survival advantage to cancer cells and a resistance to apoptosis,
perhaps forming an essential pathway for cancer, but not normal
cells. Therefore, by reversing this mitochondrial remodeling, it is
possible to“unlock” these cells from a state of apoptosis resistance,
selectively inducing cancer cell death. A critical mitochondrial
enzyme and a gatekeeper of GO is pyruvate dehydrogenase (PDH),
which exists in a complex with its inhibitor, PDH kinase (PDK).
There is now evidence that several oncogenes or transcription fac-
tors critical for cancer progression, like loss of p53 (Contractor and
Harris, 2012) or activation of hypoxia-inducible factor 1α (HIF1α;
Kimet al., 2006), can induce PDKexpression and thus inhibit PDH
and GO. Here we discuss the pre-clinical and clinical evidence that
promoting GO with PDK inhibitors or similar approaches may be
a novel approach in metabolic oncology.
A METABOLIC SHIFT TOWARD GLYCOLYSIS OFFERS A
PROLIFERATIVE ADVANTAGE TO CANCER CELLS
Most cancer cells use glycolysis as the primary energy source, an
event that occurs early during the evolutionary progression of
cancer. Gatenby and Gillies (2004) proposed that since early car-
cinogenesis often occurs in a hypoxic microenvironment, these
cells must rely on anaerobic glycolysis as a primary energy source.
This adaptation is initiated, in part, by activation of HIF, a tran-
scription factor activated upon hypoxia or “hypoxia-mimicking”
states. Once activated,HIF can regulate the expressionofmanygly-
colytic enzymes, glucose transporters, andmitochondrial enzymes
(Semenza, 2012). One such enzyme important in regulating mito-
chondrial activity and induced by HIF is PDK (Kim et al., 2006).
PDK is a gate-keeping mitochondrial enzyme that regulates the
ﬂux of carbohydrates via pyruvate from the cytoplasm into the
mitochondria, where GO occurs. By inhibiting its target enzyme
PDH, PDK prevents the coupling of glycolysis to GO. Therefore
glycolysis is completed in the cytoplasm, where pyruvate is metab-
olized further without being oxidized in the mitochondria. This
metabolic shift is a fundamental response in most tissues under
hypoxia.
However, most cancer cells maintain the same metabolic phe-
notype when studied under normal, normoxic conditions. For
example, the HIF1α-driven induction of PDK that occurs in the
hypoxic microenvironment in early stages of carcinogenesis is
maintainedwhen tumor angiogenesis initiated byHIF1α increases
oxygen supply to the growing tumor. There is now evidence that
activation of several oncogenes can actually result in a similar
suppressionofmitochondrial function and inhibitionof GO, inde-
pendent of hypoxia. In other words, non-hypoxic signaling of
several diverse oncogenes can mimic the effects of hypoxia and
HIF1α and sustain the same metabolic phenotype, continuing to
offer a growth advantage and apoptosis inhibition in the growing
tumor.
For example, p53 inhibits the expression of the glycolytic
enzyme phosphoglycerate mutase (Kondoh et al., 2005), while
increasing the expression of the glycolytic inhibitor Tp53-induced
glycolysis and apoptosis regulator (TIGAR; Bensaad et al., 2006).
Additionally, p53 can regulatemitochondrial activity by increasing
the expressionof themitochondrial cytochrome coxidase subunits
(Okamura et al., 1999; Matoba et al., 2006) and the mitochon-
drial DNA repair protein p52R2 (Bourdon et al., 2007). In other
words, loss of p53, one of the most commonmolecular abnormal-
ities in cancer, contributes to the glycolytic environment in cancer
promoting glycolysis and inhibiting mitochondrial GO and func-
tion (Burns and Richter, 2008; Vousden and Ryan, 2009). Recent
data also show that loss of p53 directly induces the expression of
PDK and also enhances the transcriptional activity and stability of
HIF1α ( Ravi et al., 2000; Kaluzova et al., 2004; Schmid et al., 2004;
Vousden and Ryan, 2009; Contractor and Harris, 2012). Further-
more, several of the enzymes involved in glycolysis also “moon-
light” as anti-apoptotic proteins or activate transcription, like
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or hexoki-
nase (Kim and Dang, 2005). Hexokinase 2, which phosphorylates
glucose to glucose-6-phosphate, initiating the glycolytic pathway,
is up-regulated in cancer and translocates to the mitochondria,
where it inhibits the mitochondrial transition pore (MTP), sup-
pressing apoptosis (Pastorino and Hoek, 2003; Kim and Dang,
2005). Hexokinase expression is increased bymany oncogenic fac-
tors including HIF and AKT as well as loss of function mutations
to p53 (Cross et al., 1995; Mathupala et al., 1997, 2001; Gottlob
et al., 2001; Elstrom et al., 2004; Osaki et al., 2004). In other words,
although in some tumors the initial hypoxic microenvironment
in carcinogenesis may inhibit GO, this inhibition may persist by
the collective action of many oncogenes. As will be apparent later
on, the suppressed mitochondria can transmit “pseudo-hypoxic”
signals that then further promote HIF activation, completing a
powerful feed-forward feedback loop that sustains the glycolytic
proﬁle and the apoptosis resistance in the tumors.
Theup-regulation of glycolysis follows the suppressionofmito-
chondrial function and as discussed can promote tumor growth.
There is also evidence that the inhibition of GO can also pro-
mote tumor growth, over and above the resulting up-regulation
of glycolysis. For example, prevention of oxidation of pyru-
vate in the mitochondria and its metabolism in the cytoplasm
has many consequences: First, by limiting the entry of pyru-
vate into the mitochondria, cancer mitochondria are deprived of
their “fuel,” thereby decreasing their activity and directly prevent-
ing mitochondrial-dependent apoptosis. This can occur because
apoptosis is initiated by the efﬂux of pro-apoptotic mediators
from the mitochondria through the MTP, a mega-channel that is
voltage- and redox-gated. The suppressed mitochondrial function
in cancer cells promotes mitochondrial hyperpolarization and a
decrease in the production of mitochondria-derived reactive oxy-
gen species (mROS), both of which increase the opening threshold
of the MTP, suppressing apoptosis (Chen, 1988; Bernardi, 1996;
Zamzami and Kroemer, 2001; Hernandez-Garcia et al., 2010).
Second, by metabolizing pyruvate in the cytoplasm by lactate
dehydrogenase (LDH), cancer cells produce lactate and the result-
ing acidosis can facilitate the breakdown of the extra-cellular
matrix, facilitating tumor expansion and metastasis (Gatenby and
Gillies, 2004). Third, the prevention of pyruvate oxidation in the
mitochondria, allows its use in anabolic biosynthetic pathways
that are critical for the synthesis of several building blocks of
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rapidly proliferating cells (Deberardinis et al., 2008; Vander Hei-
den et al., 2009).
The GO inhibition comes at the expense of efﬁcient energy
production. GO provides ∼36 adenosine triphosphate (ATP) per
glucosemolecule, compared to twoATP per glucosemolecule pro-
duced during glycolysis. Therefore by increasing glycolysis, cancer
cells may be able to generate a sufﬁcient amount of ATP. To do this,
cancer cells increase the expression of glucose transporters and gly-
colytic enzymes, to increase the uptake of glucose and enhance the
glycolytic production of ATP. This explains why the PET imaging,
which can measure glucose uptake in the tumor, remains perhaps
the most sensitive tool to diagnose cancer. The therapeutic explo-
ration of this metabolic remodeling has been signiﬁcantly limited
by the assumption that the glycolytic proﬁle is a result of cancer
progression and not a cause or a facilitator of cancer progression.
In summary, this newly discovered role of metabolism in
both carcinogenesis and cancer progression, may be an essential
requirement for tumor progression. Thus targeting the metabolic
proﬁle of cancer may be the basis for the development of effective
and selective cancer therapies. The identiﬁcation of therapeutic
targets in cancer metabolism will become apparent by a more
detailed review of the mechanisms that regulate apoptosis and
pro-proliferative mitochondrial signaling.
MITOCHONDRIA AND THE REGULATION OF APOPTOSIS AND
PRO-PROLIFERATIVE REDOX SIGNALING
The intrinsic apoptotic pathway in cells is regulated largely by
functional mitochondria (Green and Kroemer, 2004). Suppress-
ing mitochondrial activity may give cancer cells a proliferative
advantage to non-cancerous cells by suppressing apoptosis. How
does the threshold for apoptosis relate to mitochondrial function?
Themitochondria regulate energy production through the oxi-
dation of both pyruvate (derived from glycolysis) and lipids. GO
begins with the entry of pyruvate into the mitochondria, where it
is decarboxylated to acetyl-CoA by PDH. Acetyl-CoA is also pro-
duced by fatty acidmetabolism inmitochondria. Acetyl-CoA then
becomes the primary substrate for the Krebs’ cycle, from which
the electron donors nicotinamide adenine dinucleotide (NADH)
and ﬂavin adenine dinucleotide (FADH2) are produced. Electrons
are “donated” to complexes I and II of the electron transport chain
(ETC), where they ﬂow down a redox-gradient from complex I to
complex IV, with molecular oxygen being the ﬁnal electron accep-
tor (i.e., respiration). During this process, H+ are pumped from
complexes I, III, and IV out of the inner mitochondrial mem-
brane creating the mitochondrial membrane potential (Δψm),
which is quite negative (>200 mV). ATP synthase then uses the
stored energy of themitochondrialΔψmto phosphorylate adeno-
sine diphosphate (ADP), producing ATP. Thus, since respiration
is coupled to oxidative phosphorylation, Δψm may be an index
of mitochondrial activity (Duchen, 1999).
Regulation of themitochondrialΔψm is complex and depends
on many factors. For example, mitochondria are critical regula-
tors of intracellular calcium levels since they function as calcium
“sinks,” particularly to the calcium secreted by the endoplasmic
reticulum (ER). As the levels of the positively charged mitochon-
drial calcium rise, the Δψm decreases. Structural remodeling,
altering the contact points between the ER and the mitochondria,
as in ER stress, can also result in changes in the Δψm (Sim-
men et al., 2005; de Brito and Scorrano, 2008; Sutendra et al.,
2011). Uncoupling proteins like uncoupling protein (UCP)1 or
UCP2–3 (which conduct H+ and short-circuit the Δψm, or con-
duct calcium, respectively) can also regulate Δψm (Boss et al.,
2000; Sack, 2006). In a glycolytic environment, inhibition of
glycogen synthase kinase 3β (GSK3β) causes a translocation of
hexokinase 2 onto themitochondrial membrane, where it attaches
to and inhibits the major pathway for the excretion of nega-
tive ions from the mitochondria, the voltage-dependent anion
channel (VDAC; Pastorino et al., 2005); thus when the VDAC
is inhibited the mitochondrial concentration of anions increases,
increasing the Δψm. All of these parameters can contribute at
variable degrees to the regulationofΔψmin response tometabolic
signals or at different disease states. As Δψm increases, the open-
ing of the MTP is decreased. MTP is a mega-channel, which
includes VDAC and may be involved in mitochondrial mem-
brane permeabilization (MMP) and the subsequent release of
pro-apoptotic factors like cytochrome c and apoptosis inducing
factor (AIF) from the mitochondria causing apoptosis (Cromp-
ton, 1999; Kroemer et al., 2007). The MTP is voltage-gated and
thus the increase in Δψm increases its opening threshold sup-
pressing apoptosis (Zamzami and Kroemer, 2001). In addition,
mROS can also promote activation of the VDAC component
of the MTP resulting in cytochrome c release (Madesh and
Hajnoczky, 2001).
Thus Δψm and mROS are both regulated by mitochondrial
function and particularly GO, and are directly involved in the
regulation of apoptosis. Intriguingly, cancer mitochondria in the
majority of cancers have hyperpolarized mitochondria compared
to non-cancer cells. This was ﬁrst described by Dr. Chen dur-
ing his attempts to deliver drugs connected to positively charged
molecules selective to cancer cells, taking advantage of the fact that
cancer mitochondria were much more negative than non-cancer
mitochondria (Chen, 1988).
Wehave shown that the increasedΔψm,whichwe also found in
several cancer cell types, was associated with a suppression of GO
and suppression of mROS as well (Bonnet et al., 2007a; Michelakis
et al., 2010; Sutendra et al., 2012). We showed that in contrast to
what was believed at the time, this hyperpolarization and the sup-
pression of GO were not a permanent result of mitochondrial
dysfunction due to the cancerous process. When we increased
GO, by “forcing” pyruvate’s entry into the mitochondria, increas-
ing GO, the Δψm decreased, the mROS production increased,
and the normal apoptotic thresholds were re-instituted in cancer
cells, reversing the resistance to apoptosis (Bonnet et al., 2007a;
Michelakis et al., 2010; Sutendra et al., 2012).
This normalization of mitochondrial function and GO had
additional signaling effects, over and above the direct regulation of
apoptosis through the opening of the MTP. For example, mROS
can reach extra-mitochondrial redox-sensitive targets like tran-
scription factors [HIF1α, p53, or nuclear factor of activated T cells
(NFAT);Wang et al., 1995, 2000; Huang et al., 1996, 2000; Xie et al.,
2001; Bonnet et al., 2007a] and Kv channels in the plasma mem-
brane (Weir et al., 2005; Bonnet et al., 2007a), further facilitating
apoptosis and decreasing the proliferative potential of cancer cells,
as we discuss below.
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In summary, there are multiple ways in which the metabolism
of cancer cells (increased glycolysis and suppressed GO) is asso-
ciated with mitochondrial remodeling (Δψm hyperpolarization,
decreased mROS production) that leads to resistance to apop-
tosis. A potentially simple way this metabolic proﬁle and the
suppression of apoptosis and redox signaling can be reversed
is by the activation of the PDH, the gate-keeping regulator of
GO. One particularly simple way is by the use of dichloroacetate
(DCA).
DICHLOROACETATE IN CANCER: PRE-CLINICAL WORK
Dichloroacetate is a small 150 Da molecule that can penetrate cell
membranes andmost tissues, even traditional chemotherapy sanc-
tuary sites like the brain. DCA activates PDH by inhibiting PDK
at a concentration of 10–250 μM, in a dose-dependent fashion
(Stacpoole, 1989). There are four PDK isoforms that are expressed
in most tissues with the most sensitive to DCA being PDK2. The
crystal structure of PDK2 bound with DCA is shown in Figure 1:
the carboxylate group of DCA forms a salt bridge with Arg-154 of
PDK2 and the chlorine molecules reside in a hydrophobic pocket
(Knoechel et al., 2006).
Dichloracetate decreased (and normalized) the high Δψm in
non-small cell lung cancer (nSCLC), breast cancer, and glioblas-
toma cancer cell lines, but had no effects on the normal low Δψm
of non-cancer cells (Bonnet et al., 2007a; Michelakis et al., 2010;
Sutendra et al., 2012). As expected, DCA promoted apoptosis of
cancer cells in vitro and decreased tumor growth in xenotransplant
FIGURE 1 | Structure of pyruvate dehdyrogenase kinase 2 (PDK2)
bound with dichloroacetate (DCA). Surface and ribbon representation of
PDK2 with DCA bound is shown. The carboxylate group of DCA forms a
salt bridge (double black line) with arginine 154 of PDK2. The structures
were generated using visual molecular dynamics (VMD) version 1.8.6 with
the coordinates acquired from Protein Data Bank (PDB#2BU8; Knoechel
et al., 2006). L53 (leucine 53), I111 (lsoleucine 111), H115 (histidine 115),
R112 (arginine 112), R154 (arginine 154). Black lines indicate salt bride
between R154 and DCA.
models in vivo (Bonnet et al., 2007a; Sutendra et al., 2012). In
these models, the mechanism of this small molecule was the spe-
ciﬁc inhibition of PDK2, as a PDK2 siRNA, completely mimicked
DCA, and addition of DCA to the PDK2 siRNA had no additional
effects (Bonnet et al., 2007a; Sutendra et al., 2012). The effects of
DCA in cancer have now been extensively studied and the initial
reports have been conﬁrmed by several independent groups in
other cancer types including colon (Sanchez-Arago et al., 2010),
prostate (Cao et al., 2008), endometrial (Wong et al., 2008; Mad-
hok et al., 2010), or metastatic breast cancer (Sun et al., 2010). In
the latter study, the investigators showed that a number of breast
cancer cell lines were sensitive to DCA, displaying decreased pro-
liferation from 20 to 80% depending on the cell line. In vivo,
DCA was effective in reversing aggressive metastatic breast can-
cer (Sun et al., 2010). The effects of DCA on tumor metastases in
this study may be through inhibition of the redox-sensitive tran-
scription factor HIF1α. In addition to increasing the expression
of glycolytic enzymes, HIF1α can also increase the expression of
pro-angiogenic and metastasis-promoting chemokines, such as
VEGF and stromal-derived factor 1 (SDF1; Forsythe et al., 1996;
Carmeliet et al., 1998; Pugh and Ratcliffe, 2003; Karshovska et al.,
2007). HIF1α regulation is highly dependent on H2O2 and α-
ketoglutarate (αKG; substrate of Krebs’ cycle; Huang et al., 1996;
Wartenberg et al., 2003; MacKenzie et al., 2007), both of which
are produced by mitochondria. For example αKG is a product of
isocitrate dehydrogenase (IDH; a Krebs’ cycle enzyme) and can
leak out of the mitochondria where it also serves as an important
co-factor for the proline hydroxylases (PHD) that destabilize HIF
(MacKenzie et al., 2007). Indeed, in other studies, DCA increased
IDH activity and αKG levels in nSCLC, breast cancer, and glioblas-
toma cells (Michelakis et al., 2010; Sutendra et al., 2012). DCA
decreased HIF1α activity resulting in decreased tumor angiogene-
sis, tumor perfusion, glucose uptake, and tumor size and increased
animal survival (Sutendra et al., 2012 Figures 2A,B). These effects
of DCA were conﬁrmed in later studies showing that it decreases
HIF1α activity in metastatic melanoma (Kluza et al., 2012) and T
cell lymphoma (Kumar et al., 2012). This is in keeping with pre-
vious work showing that inhibition of PDK with short-hairpin
RNA decreases HIF1α activity and tumor growth in squamous
cell carcinoma (McFate et al., 2008). Therefore inhibition of PDK
and activation of mitochondrial signals decreases HIF1α activity
resulting in decreased tumor angiogenesis and tumor growth and
may also potentially explain the decreased metastases observed in
metastatic breast cancer (Sun et al., 2010; Figure 2C).
The suppression of mROS in cancer cells may promote a
decrease in the activity of p53 in nSCLC and breast cancer cells
and by increasing mROS production, DCA was also shown to
increase p53 activity (Sutendra et al., 2012). The effect of DCA on
p53 activity was also conﬁrmed in T cell lymphoma (Kumar et al.,
2012). The increase in p53 can sustain mitochondrial GO as p53
was recently shown to decrease the expression of PDK2 (Contrac-
tor andHarris, 2012). Activation of p53 can also result in decreased
HIF1α activity since p53 can directly inhibitHIF1α transcriptional
activity and promote HIF1α degradation (Kaluzova et al., 2004;
Schmid et al., 2004; Sutendra et al., 2012).
In cancer cells the decrease in mitochondrial metabolism
(i.e., decreased GO) would result in decreased ETC activity
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FIGURE 2 | (A) DCA increases the survival (left) and decreases the tumor
growth (right) of xenotransplant animals with nSCLC tumors. (B) DCA-treated
animals have tumors with decreased vascularity (top) and decreased nuclear
localization of hypoxia-inducible factor 1α (HIF1α; red, nuclear stain DAPI:
blue) and angiogenesis (lectin: green, middle panel). DCA-treated animals
have decreased glucose uptake in the tumors as indicated by PET imaging
and 18-ﬂurodexoglucose uptake (bottom panel). (C) DCA-treated animals have
decreased metastases of the lung after tail vein injection of metastatic breast
cancer. Figure modiﬁed with permission from (Sun et al., 2010; Sutendra
et al., 2012).
and decreased mROS (i.e., mostly superoxide) and ultimately
decreased H2O2 production via the dismutation of superoxide
(although the role of manganese superoxide dismutase (MnSOD)
in cancer remains controversial and only partially explored; Hol-
ley et al., 2012). One would expect that the decreased activity of
the ETC in cancer would also result in decreased pumping of
H+ ions from the inner membrane, which would cause mem-
brane depolarization, as less positive ions would leave the matrix.
Yet, there is very strong evidence from the 1980s (Chen, 1988)
and more recently (Pastorino and Hoek, 2003; Bonnet et al.,
2007a; Michelakis et al., 2010; Sutendra et al., 2012) that can-
cer mitochondria are hyperpolarized, a fact that is in keeping
with the apoptosis resistance characterizing these cells. There is
no question that this important area needs more research, as
clariﬁcation would be important for the emerging approaches
to therapeutically target mitochondria or use them as the basis
for diagnostic/imaging techniques. Here are some thoughts that
we believe may help explain this apparent conﬂict: ﬁrst, while
less H+ are pumped out, less H+ also accumulates in the matrix
as less electron and H+ donors (NADH, FADH2) are produced,
following a potential decrease in pyruvate’s entry in mitochon-
dria. Second, the decrease in mROS may also promote a closure
of the redox-sensitive VDAC, i.e., the major anion channel in
the mitochondria (Madesh and Hajnoczky, 2001). In addition,
the resultant concomitant up-regulation of glycolysis is associ-
ated with a translocation of hexokinase 2 from the cytoplasm to
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the mitochondrial membranes, where it has been shown to bind
and further inhibit VDAC (Pastorino and Hoek, 2003; Pastorino
et al., 2005). In other words, less anions will also be leaving the
mitochondria, contributing to an increase in Δψm. Furthermore,
the accumulation of glycolysis-produced ATP in cytoplasmic
microdomains associated with the mitochondria could serve as
a signal to inhibit the ATP synthase (this intriguing possibility is
difﬁcult to be proven at this point given the absence of organelle-
speciﬁc ATP imaging technologies). An increase in cytoplasmic
ATP (and decrease in ADP) inhibits the gradient for ATP efﬂux
from the mitochondria and thus decreases the drive for H+ re-
entry into the matrix. Lastly more work in needed to clarify
any potential role of mitochondrial uncoupling via uncoupling
proteins, which short-circuit the H+ conduction through the
mitochondrial membrane (Robbins and Zhao, 2011).
This decrease in mROS in cancer, in addition to the effects
on HIF1α and p53, also results in inhibition of redox-sensitive
K+ channels in the plasma membrane, speciﬁcally Kv1.5 (Bonnet
et al., 2007a). The resulting decrease in K+ conductance causes
an increase in the intracellular K+, which contributes to the
suppression of apoptosis since K+ is a tonic inhibitor of cas-
pases (Remillard and Yuan, 2004). The inhibition of Kv1.5 also
results in depolarization of the plasma membrane and activa-
tion of L-type calcium channels, increasing intracellular calcium.
Calcium can activate many enzymes involved in proliferation
and mitochondrial remodeling, such as NFAT; Macian, 2005.
NFAT is a transcription factor that can regulate the expression
of many genes, increasing the expression of the anti-apoptotic
protein B cell lymphoma-2 (bcl-2) and decreasing the expression
of Kv1.5, thereby sustaining an apoptosis-resistant state (Bonnet
et al., 2007b). All of these features may be secondary to mitochon-
drial remodeling. As discussed above, the initial switch toward
glycolysis will also activate additional mechanisms (like the hex-
okinase translocation to the mitochondria), which also sustains
mitochondria hyperpolarization and MTP inhibition. Therefore
suppression of mitochondrial GO and the downstream mito-
chondrial signaling results in activation of HIF1α and NFAT and
inhibition of p53, promoting proliferation, angiogenesis, and
metastases, while the increased Δψm promotes MTP inhibition
and apoptosis resistance. All of these effects are reversed by activa-
tion of PDH by DCA (Bonnet et al., 2007a; Michelakis et al., 2010;
Sutendra et al., 2012; Figure 3).
Interestingly, in a recent study, two molecules of DCA were
linked to cisplatin, a compound that induces nuclear cross-
linking of DNA, resulting in apoptosis (Fuertes et al., 2003). This
new molecule, mitaplatin, was selective to cancer cells inducing
mitochondria-dependent apoptosis (through the effects of DCA),
and nuclear degradation (through the effects of cisplatin), further
validating the beneﬁcial effects of DCA in cancer and provid-
ing evidence that DCA may have additional beneﬁcial effects in
combination with current anti-cancer therapies (Dhar and Lip-
pard, 2009).
CLINICAL EXPERIENCE WITH PDK INHIBITION BY DCA
DCA IN TREATMENT OF CONGENITAL MITOCHONDRIAL DISEASES
In the past 40 years, DCA has been used extensively for the
treatment of mitochondrial diseases. As ﬁrst described in 1969
FIGURE 3 | Mechanism of DCA in cancer: DCA inhibits pyruvate
dehydrogenase kinase (PDK) resulting in activation of pyruvate
dehydrogensae (PDH). By increasing mitochondrial-based GO and
acetyl-CoA levels, DCA increases Krebs’ cycle and electron transport chain
activity, increasing mitochondrial-derived reactive oxygen species (mROS)
and α-ketoglutarate (αKG) levels. This results in decreased activation of
pro-proliferative transcription factors, like NFAT and HIF1α and increasing
the activity of Kv channels and the tumor suppressor protein p53.
by Stacpoole (Stacpoole, 1969), by inhibiting PDK and coupling
glycolysis to GO, DCA could lower lactate levels and the symp-
toms associated with lactic acidosis in patients withmitochondrial
diseases,mostly syndromes caused by the lack or decreased expres-
sion of critical enzymes involved in GO, like PDH. As a result of
the inhibited GO these patients suffer from lactic acidosis since
pyruvate cannot be oxidized in the mitochondria and is metab-
olized to lactic acid by lactic dehydrogenase. In addition lactic
acidosis complicates several non-mitochondrial diseases in which
tissue hypoxia and hypo-perfusion results to metabolic acidosis,
including sepsis or heart failure. Thus, DCA has been tested in
clinical trials in both mitochondria and non-mitochondrial dis-
eases in order to limit lactic acidosis (Stacpoole et al., 2003). As
expected, while DCA was effective in decreasing lactic acid lev-
els, it did not improve the outcomes of these patients, as it can
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only limit a symptom of these diseases and not their primary
cause (lack of a critical enzyme or the original cause for decreased
tissue perfusion etc). In the ﬁrst study 30 patients with MELAS
syndrome were treated with 25 mg/kg/day of oral DCA. Most of
these patients had developed symptomatic peripheral neuropathy,
compared to the placebo group. This resulted in early termination
of the study. Seventeen out of the 19 patients who had reported
peripheral neuropathy had resolution of the neuropathy follow-
ing 9 months discontinuation of DCA. No other toxicities were
reported in that study (Kaufmann et al., 2006). Overall, this non-
demyelinating peripheral neuropathy is known tobe reversible and
dose-dependent. In a second placebo-controlled double-blinded
study, oral DCA treatment (25 mg/kg/day) of 21 children with
congenital lactic acidosis demonstrated mild peripheral neuropa-
thy at 6 months. However, serial nerve conduction studies showed
no detectable differences in incidence of neuropathy between
placebo and DCA-treated groups (Stacpoole et al., 2006). This
would indicate that the higher incidence of peripheral neuropathy
in the MELAS group might be due, in part, to the natural his-
tory of the disease, as patients with MELAS also have diabetes or
diabetes-related peripheral neuropathy.
DCA IN GLIOBLASTOMA MULTIFORME
The solid evidence in pre-clinical in vitro and in vivo models,
suggested thatDCAmight be beneﬁcial in humancancer. Glioblas-
tomas are aggressive, highly vascularized tumors for which there
are no cures and available treatments prolong life only mini-
mally. The expected survival in newly diagnosed GBM is just over
a year whereas the survival of recurrent disease (despite treat-
ments) is less than 6 months (Wen and Kesari, 2008). We ﬁrst
studied 49 freshly excised GBM tumors and compared them to
normal brain tissues obtained during epilepsy surgery, studying
them immediately with functional confocal microscopy imaging.
GBM tumors had increased Δψm compared to normal brain tis-
sue (Michelakis et al., 2010). Similar to pre-clinical studies, DCA
acutely depolarized mitochondria in these GBM tumor tissues,
but had no effect on normal tissues (Michelakis et al., 2010). In
addition, the target of DCA (i.e., PDK2) was expressed at much
higher levels in the GBM compared to the normal brain tissues
(Michelakis et al., 2010). We then administered DCA orally at
a dose of 12.5 mg/kg twice a day in ﬁve patients with primary
GBM (Michelakis et al., 2010). Three of these patients had recur-
rent GBM with disease progression after several chemotherapies.
None of these patients developed hematologic, hepatic, renal, or
cardiac toxicity. Peripheral neuropathy was noted, but reversed
upon a dose-decrease to 6.25 mg/kg of DCA twice a day. At a
dose of 6.25 mg/kg orally twice a day the trough levels of DCA
after 3 months of therapy were comparable to those in DCA treat-
ment of adults with mitochondrial defects and in the range of
the Ki of DCA for PDK2 inhibition (0.2 mM; Bowker-Kinley
et al., 1998). Three of the patients showed evidence of radiologic
regression, while four of the ﬁve patients were clinically stable
at 18 months of DCA therapy (Michelakis et al., 2010). GBM
tissues from three of these patients were obtained prospectively
(pre-DCA) and compared with the tissues after DCA treatment
(post-DCA) from the same patients. In post-DCA GBM tis-
sues, there was a signiﬁcant decrease in Δψm and increase in
mROS. Chronic treatment of DCA resulted in decreased prolif-
eration and increased apoptosis in vivo compared to the same
patients pre-DCA GBM biopsies. As expected, by inhibiting PDK,
DCA increased PDH activity in the post-DCA GBM tissues com-
pared to the pre-DCA GBM tissues. It also appears that DCA
may have effects on putative GBM stem cells (GBMSC), which
are responsible for tumor recurrence. GBMSC had signiﬁcantly
increased mitochondrial Δψm compared to the primary GBM
tumors, both in situ in freshly excised tumor tissues and in vitro
(GBMSC were isolated using magnetic beads from the excised
tumors and allowed to form neurospheres), compatible with the
fact that these GBMSC are even more apoptosis resistant than
primary tumor cells. DCA depolarized mitochondria, increased
mROS, decreased proliferation, and induced apoptosis in GBM-
SCs, similar to its effects on the primary GBM cells. Additionally,
post-DCA GBM tumor biopsies had decreased HIF1α expression
and activity resulting in a signiﬁcant decrease in tumor vascu-
larity compared to pre-DCA GBM biopsies (Figure 4). This was
expected as DCA increased both H2O2 and αKG, molecules that
can increase HIF1α inhibition (Huang et al., 1996; MacKenzie
et al., 2007). Mutations in the genes for IDH (an enzyme that
catalyzes the decarboxylation of isocitrate to αKG) have been
described in GBM (Dang et al., 2009; Thompson, 2009) and
these mutations could result in activation of HIF1α, in part by
decreasing αKG levels (MacKenzie et al., 2007). In addition, DCA
increased p53 levels and its downstream target, p21, which may
also contribute to the decreased proliferation shown in the DCA-
treated tissues in vitro and in vivo (Michelakis et al., 2010). With
no signiﬁcant toxicity, its relative selectivity and its potential ben-
eﬁcial effects on tumor proliferation, angiogenesis, and apoptosis,
DCA holds promise in the emerging new frontier in metabolic
oncology. This mechanistic study in patients with GBM, although
small, established the fact that after oral therapy DCA can reach
levels high enough to have the same effects in human tumors as in
the pre-clinical studies, showing feasibility of this novel approach
in humans.
THE MECHANISM OF DCA MAY INVOLVE ADDITIONAL ASPECTS OF
METABOLISM
While this is not reviewed here, the DCA results may also be
compatible with exciting data suggesting that targeting fatty acid
β-oxidation (FAO) may also be important as a potential cancer
treatment (Samudio et al., 2010). In most cell types there appears
to be balance in the regulation of the primary mitochondrial fuel
for oxidative phosphorylation, i.e., pyruvate versus fatty acids.
In fact, Randle (1998) ﬁrst described an elegant pathway by which
inhibition of FAOresults in activation of PDHand thus promotion
of GO, and vice versa (the Randle feedback). In this mechanism,
Randle (1998) described how acetyl-CoA, NADH, and ATP pro-
duced by FAO could directly activate PDK, therefore decreasing
GO. Thus, the inhibition of FAO indirectly promotes GO in a
manner that mimics the direct activation of GO by DCA. Lastly,
the suppression of GO in cancer allows pyruvate to also enter
other important pathways, like amino-acid biosynthesis reactions
that are critical for protein synthesis in rapidly proliferating cells
and their independence of exogenous trophic factors (Quash et al.,
2003). In other words, refueling pyruvate into the mitochondria
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FIGURE 4 | (A) DCA decreases nuclear localization of HIF1α (HIF1α, red; merged with DAPI, blue; right) and angiogenesis in GBM (vWF, green; merged
with DAPI, blue; right). (B) DCA decreases tumor growth in a patient with GBM after 9 months of treatment. Figure modiﬁed with permission from
(Michelakis et al., 2010).
with DCA, may also lead to disruption of these biosynthesis
pathways that are activated in cancer cells, suggesting that addi-
tional mechanisms may play a role in the overall effects of DCA
in vivo.
OTHER METABOLIC THERAPIES THAT MIMIC PDK
INHIBITION AND PROMOTE MITOCHONDRIAL GO
Although DCA can selectively increase mitochondrial metabolism
in cancer cells, there are other ways to increase mitochondrial
activity. LDH is an enzyme that completes pyruvate metabolism
to lactate in the cytosol. When LDH is inhibited, pyruvate may
be “forced” to enter the mitochondria and undergo decarboxyla-
tion to acetyl-CoA, increasing GO. Remarkably, similar to DCA,
inhibition of LDH-A by short-hairpin RNAs increased mito-
chondrial activity, depolarized mitochondria, inducing apoptosis,
and decreasing tumor growth in vitro and in vivo, once again
mimicking DCA (Fantin et al., 2006).
In addition, recent data have shown that the M2 isoform of
pyruvate kinase (PKM2) is highly expressed inmany cancers com-
pared to the M1 isoform of pyruvate kinase (PKM1), which is
mostly expressed in non-cancerous tissues (Christofk et al., 2008;
Vander Heiden et al., 2010). It is now known that this less active
form of pyruvate kinase (PKM2), results in mitochondrial sup-
pression and tumor growth (Christofk et al., 2008; Anastasiou
et al., 2012). Replacement of PKM2 with PKM1 or increasing
PKM2 activity both result in increased mitochondrial GO and
decreased tumor growth (Christofk et al., 2008; Anastasiou et al.,
2012). This suggests that similar to PDK, PKM2 may also be a
viable and selective target against cancer.
It is now becoming increasingly recognized that targeting the
metabolism of cancer cells may offer a selective and effective anti-
cancer therapy. However, it is important to clarify that inhibiting
glycolysis would not be selective to cancer cells or increase mito-
chondrial metabolism. In fact, it would be toxic to non-cancerous
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tissues that depend on glycolysis for energy production (i.e., skele-
tal muscle or brain tissue). In other words, drugs that inhibit
glycolysis do not necessarily result in an increase in GO and
could simply result in disruption of energy production and non-
selective cell death, an undesired feature of promising cancer
drugs. It is more important to promote coupling of glycolysis to
GO (which in turn would eventually result in decreased glycolysis,
by decreasing the activity of pro-glycolytic transcription factors,
like HIF1α) as this is the strategy that would re-activate the sup-
pressed mitochondria-dependent apoptosis just in cancer cells as
opposed to inducing energy starvation and cell death in all tissues
utilizing glycolysis for energy production.
CONCLUSION
In summary, a diverse number of signaling pathways and onco-
genes (i.e., loss of p53 function, activation of HIF1α, cmyc, etc.)
result in resistance to apoptosis and a glycolytic phenotype. DCA
can reverse thismetabolic remodeling andmay be an effective anti-
cancer agent in a number of tumors. The pre-clinical and recent
clinical evidence that DCA, as a single agent, might be effective
in GBM (Bonnet et al., 2007a; Michelakis et al., 2010), suggests its
use in other glycolytic forms of cancer. However, the greatest effect
may be synergistic with existing chemotherapy as DCA “unlocks”
cancer cells from a state of apoptosis resistance. Preliminary evi-
dence in GBMSC, in which the highest induction of apoptosis
was achieved with the combination of DCA and temozolomide,
supports this idea (Michelakis et al., 2010). Therefore, in future
clinical trials, DCA could be given simultaneously with standard
therapy in an attempt to increase its effectiveness and potentially
decrease the required dose, limiting the toxicity of standard ther-
apies, which often are non-selective to non-cancerous tissues. The
ability to target the unique metabolic proﬁle of cancer cells, sug-
gests that imaging and diagnostic studies, such as PET imaging,
may track themetabolicmodulationof therapies likeDCA. Finally,
pre-clinical biopsies frompatients can acutely be treatedwithDCA
and mitochondrial function can be quickly assessed, potentially
predicting the clinical response to DCA, which could be used to
facilitate patient selection.
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